Adverum Biotechnologies Inc
NASDAQ:ADVM

Watchlist Manager
Adverum Biotechnologies Inc Logo
Adverum Biotechnologies Inc
NASDAQ:ADVM
Watchlist
Price: 4.36 USD Market Closed
Market Cap: 96.3m USD

Adverum Biotechnologies Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Adverum Biotechnologies Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Adverum Biotechnologies Inc
NASDAQ:ADVM
Cash from Operating Activities
-$137.9m
CAGR 3-Years
-6%
CAGR 5-Years
-14%
CAGR 10-Years
-16%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Adverum Biotechnologies Inc
Glance View

Market Cap
95.9m USD
Industry
Biotechnology

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2014-07-31. The firm develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The firm's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

ADVM Intrinsic Value
0.06 USD
Overvaluation 99%
Intrinsic Value
Price

See Also

What is Adverum Biotechnologies Inc's Cash from Operating Activities?
Cash from Operating Activities
-137.9m USD

Based on the financial report for Sep 30, 2025, Adverum Biotechnologies Inc's Cash from Operating Activities amounts to -137.9m USD.

What is Adverum Biotechnologies Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-16%

Over the last year, the Cash from Operating Activities growth was -61%. The average annual Cash from Operating Activities growth rates for Adverum Biotechnologies Inc have been -6% over the past three years , -14% over the past five years , and -16% over the past ten years .

Back to Top